The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2011Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway
Objective/Rationale:
Envoy Therapeutics’ target discovery technology enables the identification of new drug targets that have very selective expression in brain circuits of therapeutic interest thereby... -
Alpha-Synuclein Imaging, 2011Consortium to Develop an Alpha-synuclein Imaging Agent
Objective/Rationale:
The ultimate goal of this project is develop a positron emission tomography (PET) radiotracer to image the distribution of alpha-synuclein in the brain. Alpha-synuclein imaging... -
Research Grant, 2011Testing Effects of Improved Levodopa Delivery with Dexterity and Gait Objective Measures
Objective/Rationale:
The objective of this project is to develop an extended-release capsule of levodopa/carbidopa (IPX066) that will result in constant blood levels of levodopa compared to current... -
Repositioning Drugs for PD, 2011Duloxetine Hydrochloride as a Novel Neuroprotective Treatment for Parkinson's Disease
Objective/Rationale:
In Parkinson’s disease (PD) dopaminergic neurons in the midbrain region substantia nigra pars compacta die. There is currently no treatment available that prevents this cell death... -
Repositioning Drugs for PD, 2011Evaluation of a Specific DAT Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
MLR-1017 is a psychostimulant drug used clinically for a variety of neuropsychiatric and other applications, but has never been tested in Parkinson’s disease (PD). Levodopa is a... -
Antibody Comparison, 2011Antibody Testing in Postmortem Human Brain
Objective/Rationale:
Mutations in the gene for LRRK2 are the most common genetic cause for Parkinson’s disease (PD) and therefore the LRRK2 protein appears to be important for normal brain function...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.